Moira Katherine Rushton

Jun 5, 2024 | winnipegfreepress.com | Anna Wilkinson |GP Oncologist |l’Université d’Ottawa |Jean Seely |Moira Katherine Rushton

This article was originally published on The Conversation, an independent and nonprofit source of news, analysis and commentary from academic experts. Disclosure information is available on the original site. ___Authors: Anna N.

Aug 26, 2023 | mdpi.com | Anna Wilkinson |Jean Seely |Moira Katherine Rushton |Phillip Williams

1. IntroductionApproximately one in every eight women will be diagnosed with breast cancer (BC) over their lifetime, with an estimated 28,600 new cases of BC in Canada in 2022 [1,2]. BC treatment is rapidly evolving, with ongoing advances in genomic testing, radiation therapy, surgery and systemic therapy. BC molecular subtype, based on hormone receptor (HR) and HER2/neu (HER2) status, is increasingly driving specialised therapy choices and informing improved subtype-specific survival [3].